Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis
The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
Objective Activated T cells are the main component of the inflammatory skin infiltrates that characterise systemic sclerosis (SSc). Our aim was to investigate the efficacy of abatacept, which tempers T-cell activation, in reducing skin fibrosis in complementary mouse models of SSc. Methods The antifibrotic properties of abatacept were evaluated in the mouse models of bleomycin-induced dermal fibrosis and sclerodermatous chronic graft-versus-host disease, reflecting early and inflammatory stages of SSc. Thereafter, we studied the efficacy of abatacept in tight skin (Tsk-1) mice, an inflammation-independent mouse model of skin fibrosis. Results Abatacept efficiently prevented bleomycin-induced skin fibrosis and was also effective in the treatment of established fibrosis. In this model, abatacept decreased total and activated T-cell, B-cell and monocyte infiltration in the lesional skin. Abatacept did not protect CB17-SCID mice from the development of bleomycin-induced dermal fibrosis, which supports that T cells are necessary to drive the antifibrotic effects of abatacept. Upon bleomycin injections, skin interleukin (IL) 6 and IL-10 levels were significantly reduced upon abatacept treatment. Moreover, treatment with abatacept ameliorated fibrosis in the chronic graft-versus-host disease model, but demonstrated no efficacy in Tsk-1 mice. The tolerance of abatacept was excellent in the three mouse models. Conclusions Using complementary models, we demonstrate that inhibition of T…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In bleomycin induced skin fibrosis in mice, abatacept lowers the influx of monocytes, T cells and B cells into lesional areas, lowers IL-6 and IL-10 levels and lowers skin fibrosis (207).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [207]
Citations
Cites
1 retracted
Ruzehaji, N., Avouac, J., Elhaï, M., Fréchet, M., Frantz, C., Ruiz, B., Distler, J. H. W., & Allanore, Y. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0659-5 · Cited by 42
Self-citationRetractedGabrielli, A., Avvedimento, E. V., & Krieg, T. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0806188 · Cited by 1,384
Systemic sclerosis: a prototypic multisystem fibrotic disorder
Varga, J., & Abraham, D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31139 · Cited by 1,163
Lymphocytes in the skin of patients with progressive systemic sclerosis
Roumm, A. D., Whiteside, T. L., Medsger, T. A., & Rodnan, G. P. (1984) · Arthritis & Rheumatism · doi:10.1002/art.1780270607 · Cited by 383
Sato, S., Hasegawa, M., & Takehara, K. (2001) · Journal of Dermatological Science · doi:10.1016/s0923-1811(01)00128-1 · Cited by 297
Transforming growth factor β as a therapeutic target in systemic sclerosis
Varga, J., & Pasche, B. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.26 · Cited by 295
Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis.
Mavalia, C., Scaletti, C., Romagnani, P., Carossino, A. M., Pignone, A. M., Emmi, L., Pupilli, C., Pizzolo, G., Maggi, E., & Romagnani, S. (1997) · Europe PMC (PubMed Central) · Cited by 261
Saito, E., Fujimoto, M., Hasegawa, M., Komura, K., Hamaguchi, Y., Kaburagi, Y., Nagaoka, T., Takehara, K., Tedder, T. F., & Sato, S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15078 · Cited by 225
Akhmetshina, A., Venalis, P., Dees, C., Busch, N., Zwerina, J., Schett, G., Distler, O., & Distler, J. H. W. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24186 · Cited by 212
Saito, E., Fujimoto, M., Hasegawa, M., Komura, K., Hamaguchi, Y., Kaburagi, Y., Nagaoka, T., Takehara, K., Tedder, T. F., & Sato, S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215078 · Cited by 210
Cited by
Pathophysiology of systemic sclerosis: current understanding and new insights
Cutolo, M., Soldano, S., & Smith, V. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1614915 · Cited by 369
“A further example, of unexpected antifibrotic activity, arises from the use of CTLA-4Ig in SSc in order to achieve an immunosuppressive action by interacting/blocking the costimulatory molecules (CD80/CD86) expressed on activated immune cells [122].”
BackgroundKhanna, D., Spino, C., Johnson, S., Chung, L., Whitfield, M. L., Denton, C. P., Berrocal, V., Franks, J., Mehta, B., Molitor, J., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41055 · Cited by 225
“Animal studies support the notion that abatacept (a CTLA4 immunoglobulin fusion protein) could be effective in the management of dcSSc, as it attenuates skin and lung fibrosis in models of scleroderma (7,8).”
BackgroundSelf-citationT cell costimulation blockade blunts pressure overload-induced heart failure
Kallikourdis, M., Martini, E., Carullo, P., Sardi, C., Roselli, G., Greco, C. M., Vignali, D., Riva, F., Ormbostad Berre, A. M., Stølen, T. O., et al. (2017) · Nature Communications · doi:10.1038/ncomms14680 · Cited by 199
The immunopathogenesis of fibrosis in systemic sclerosis
Brown, M., & O’Reilly, S. (2019) · Clinical and Experimental Immunology · doi:10.1111/cei.13238 · Cited by 190
Unraveling SSc Pathophysiology; The Myofibroblast
van Caam, A., Vonk, M., van den Hoogen, F., van Lent, P., & van der Kraan, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02452 · Cited by 153
Metadata
- Authors
- Ponsoye, M., Frantz, C., Ruzehaji, N., Nicco, C., Elhai, M., Ruiz, B., Cauvet, A., Pezet, S., Brandely, M. L., Batteux, F., Allanore, Y., & Avouac, J.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Hôpital Cochin (FR)
- Corresponding author
- Avouac, Jérôme
- ORCID
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 75
- Issue
- 12
- Pages
- 2142-2149
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2345318809
- Cited by
- 70
- References
- 42
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 1 · 2023: 9 · 2022: 9 · 2021: 10 · 2020: 13 · 2019: 6 · 2018: 8 · 2017: 5 · 2016: 3
- FWCI
- 6.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Annals of the Rheumatic Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Rheumatology › Dupuytren's Contracture and Treatments
- Health Sciences › Medicine › Dermatology › Dermatologic Treatments and Research
- Keywords
- abatacept, systemic sclerosis, skin fibrosis, T cell activation, bleomycin-induced fibrosis, sclerodermatous chronic graft-versus-host disease, skin inflammation, interleukin-6, IL-10, antifibrotic therapy, fibrosis regression
- MeSH terms
- Abatacept, Animals, B-Lymphocytes, Bleomycin, Disease Models, Animal, Fibrosis, Graft vs Host Disease, Lymphocyte Activation, Scleroderma, Systemic, Skin Diseases, T-Lymphocytes, Interleukin-6, Interleukin-10, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis. https://app.cochat.ai/papers/10.1136/annrheumdis-2015-208213
- The paper
- Ponsoye, M., Frantz, C., Ruzehaji, N., Nicco, C., Elhai, M., Ruiz, B., Cauvet, A., Pezet, S., Brandely, M. L., Batteux, F., Allanore, Y., & Avouac, J. (2016). Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2015-208213
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.